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background: Isoﬂavones from soy and red clover exert modest hormonal effects in women, but the relevance to risk of breast cancer
is unclear. The aim of this meta-analysis was to assess the effects of isoﬂavone-rich foods or supplements on a biomarker of breast cancer
risk, women’s mammographic density.
methods: Electronic searches were performed on The Cochrane Library, Medline and EMBASE (to June 2009), and reference lists and
trial investigators were consulted to identify further studies. Randomized controlled trials (RCTs) of isoﬂavone-rich foods or supplements
versus placebo with a duration of at least 6 months were included in our analysis. Inclusion/exclusion, data extraction and validity assessment
were carried out independently in duplicate, and meta-analysis used to pool study results. Subgrouping, sensitivity analysis, assessment of
heterogeneity and funnel plots were used to interpret the results.
results: Eight RCTs (1287 women) compared isoﬂavones with placebo for between 6 months and 3 years. Meta-analysis suggested no
overall effect of dietary isoﬂavones on breast density in all women combined [mean difference (MD) 0.69%, 95% conﬁdence interval (CI)
20.78 to 2.17] or post-menopausal women (MD 21.10%, 95% CI 23.22 to 1.03). However, there was a modest increase in
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Advanced Access publication on May 28, 2010 doi:10.1093/humupd/dmq011mammographic density in premenopausal women (MD 1.83%, 95% CI 0.25–3.40) without heterogeneity but this effect was lost in one of
three sensitivity analyses.
conclusions: Isoﬂavone intake does not alter breast density in post-menopausal women, but may cause a small increase in breast
density in premenopausal women. Larger, long-term trials are required to determine if these small effects are clinically relevant.
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Introduction
The structural similarity of plant-derived isoﬂavones to human 17b
estradiol has stimulated signiﬁcant interest in their importance to
women’s health (Balk et al., 2005; Messina et al., 2006), with some evi-
dence that dietary isoﬂavones can inﬂuence hormonal levels in pre- and
post-menopausal women (Hooper et al., 2009). However, the safety
and efﬁcacy of soy-derived isoﬂavones from different sources has not
been fully evaluated, particularly in relation to breast cancer risk.
Increased circulating estradiol concentrations are associated with
increased risk of breast cancer in post-menopausal women (Endogen-
ous Hormones Breast Cancer Collaborative Group, 2002), whereas
higher soy isoﬂavone intakes are associated with lower breast
cancer risk in epidemiological studies. Cross-cultural studies suggest
3-fold lower rates of breast cancer in Asian populations, where soy
consumption is high (Messina et al., 2006; Trock et al., 2006). A
recent meta-analysis of cohort and case–control data on soy intake
and breast cancer showed soy to be associated with a small reduction
in risk (Trock et al., 2006) whereas another found a signiﬁcant trend of
reduced breast cancer risk with increasing soy food intake (Wu et al.,
2008). In a large recent analysis of breast cancer patients from the
Shanghai Breast Cancer Survival Study, soy food consumption (with
average intakes of 47 mg/day of isoﬂavones) was inversely associated
with risk of death [hazard ratio (HR) 0.71, 95% conﬁdence interval
(CI) 0.54–0.92 for the highest compared with the lowest quartiles
of soy intake] and breast cancer recurrence (HR 0.68, 95% CI
0.54–0.87; Shu et al., 2009). Despite these epidemiological data,
results from the available intervention trials have been equivocal. No
large, long-term randomized controlled trials (RCTs), powered to
assess breast cancer as an outcome, have been published. It
remains unclear whether isoﬂavones from different sources increase
or decrease breast cancer risk in humans. A recent meta-analysis of
side effects of phytoestrogens observed only 16 cases of breast
cancer diagnoses, insufﬁcient to assess effects on this outcome
(Tempfer et al., 2009).
The biological effects induced by isoﬂavones may result in long-term
genomic actions mediated by intracellular estrogen-receptor (ER)
induced changes in gene expression or as rapid non-genomic actions
that modify a wide array of intracellular signal transduction cascades
(Setchell and Cassidy, 1999; Losel et al., 2003; Messina, 2007). Avail-
able evidence suggest that their ER binding potential may be more
important in vivo (Losel et al., 2003; Penttinen-Damdimopoulou
et al., 2009) since the isoﬂavone concentrations required to stimulate
certain non-genomic activities, such as inhibition of cellular protein
tyrosine kinases (.10 mM) and topoisomerase-II typically exceed
the plasma levels that can be attained via a habitual dietary intake of
soy-rich foods ( 225 mM; Messina et al., 2009).
There are conﬂicting experimental data on the effects of isoﬂavones
on breast cancer cells in vitro and estrogen-sensitive induced mammary
tumours in vivo (Hsieh et al., 1998; Allred et al., 2001; Kanno et al.,
2003; Messina et al., 2006, 2009; Cline and Wood, 2009; Power
et al., 2006a, b, 2007; Saarinen et al., 2009). Isoﬂavones are not estro-
genic in cynomolgus monkeys, even following high isoﬂavone intake;
these reduced estrogen-induced proliferation responses occur via
effects on estrogen metabolism, or are mediated through ER inter-
actions (Cline and Wood, 2009). Paradoxically, in rodents and
in vitro cell models isoﬂavones induce estrogen-like effects in breast
cancer cells lines and cause uterine enlargement in rodents
(Wang et al., 1996; Hsieh et al., 1998; Allred et al., 2001; Kanno
et al., 2003; Power et al., 2006a, b, 2007; Seo et al., 2006; Saarinen
et al., 2009). This mixed estrogen agonist/antagonist activity of isoﬂa-
vones was recently reported in an estrogen reporter mouse model,
where ER signalling was modulated following ingestion of isoﬂavones
(Penttinen-Damdimopoulou et al., 2009); soy isoﬂavones exerted anties-
trogenic effects in the presence of estradiol and estrogenic effects in the
absence of estradiol. Rodent studies and epidemiological data suggest
that these differential biological effects may be explained by timing of
exposure or dose of isoﬂavones in relation to endogenous estrogens
(Hsieh et al., 1998; Lamartiniere et al., 1998, 2002; Lamartiniere,
2000; Wu et al., 2002; Korde et al., 2009). These observed estrogenic
effects in animal models have heightened concerns over the potential
estrogenic effects of isoﬂavone consumption in humans.
Although there are currently no reliable biomarkers of breast
cancer risk, mammographic density has consistently been one of the
best independent biomarkers; moderate to high-density confers a
1.8 to 5-fold risk for developing breast cancer compared with low-
density in both pre- and post-menopausal women (McCormack and
dos Santos Silva, 2006; Vachon et al., 2007; Cummings et al., 2009).
Despite the evidence that it is an established risk factor for breast
cancer development, there remains some uncertainty about the use
of mammographic density as an intermediate marker of risk for the
disease (Becker and Kaaks, 2009). Available data suggest that
several hormonal and dietary factors can modify breast density;
density increases with estrogen and progestin therapy and decreases
following exposure to tamoxifen or ovarian suppression (Boyd et al.,
1997, 2001; Greendale et al., 2003).
Given the current controversies and complex relationship
between isoﬂavone intake and breast cancer risk and the lack of
RCTs on the effects of isoﬂavones on breast cancer incidence, we
conducted a systematic review and meta-analysis of the available
randomized controlled studies of isoﬂavones using mammographic
breast density as a surrogate marker. The primary objective was
to assess the effect of isoﬂavone-rich foods and isoﬂavone extracts
from soy and red clover on breast density in women. Secondary
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menopausal women, by baseline breast cancer risk, by duration of
exposure and by source and dose of isoﬂavone. No protocol for
this review has been published.
Methods
Search and inclusion criteria
An electronic search was performed on The Cochrane Library, Medline
and EMBASE (from inception of each database until June 2009). The
search was in the format: [isoﬂavones or soy or red clover] and [RCT
ﬁlter] and [breast density or breast cancer]. The search was not limited
to English language publications but no relevant non-English publications
were located. In addition to the electronic searches the reference lists
of included studies and relevant related systematic reviews were
checked for further trials. Attempts were made to contact authors of all
included studies for information about ongoing trials, as well as further
details on their published studies.
Included studies were randomized controlled parallel arm trials of at least
6 months duration which compared increased intake of traditional soy
foods, isoﬂavone-rich soy products or isolated isoﬂavones from soy or
red clover compared with usual or control/placebo diet. Included partici-
pants were women of any age, at any baseline risk of breast cancer, with
or without a history of breast cancer and outcomes included breast density.
All potential titles and abstracts were assessed for their relevance by
two independent reviewers. Potentially relevant papers were collected
in full text for further assessment of inclusion. One reviewer initially
excluded studies that were clearly not relevant (such as in vitro or case–
control studies) then the remainder were assessed independently for
inclusion by two reviewers using an inclusion/exclusion form designed
for the review. Reviewers met to discuss differences in data extraction,
all differences were decided by discussion.
Data collection and assessment of validity
Data extraction and validity assessment were carried out together onto a
data extraction form developed for the review. Extracted data included
bibliographic details, participants’ characteristics (menopausal status,
mean age, baseline cancer risk, country), type of intervention (source, iso-
ﬂavone dose, type of placebo, compliance), duration of intervention,
numbers of participants randomized to and completing each study arm,
method used to assess breast density, side effects and breast cancer diag-
noses. In addition, details of the number of participants, mean breast
density change (absolute change or as change per year) and variance of
that change (or end breast density and its variance where change data
were not available) were collected for each arm of each included study
at the latest time point available. Baseline risk of breast cancer was
deﬁned as follows: high risk included participants with family history of
breast cancer, presence of genetic risk markers or high risk according to
the Gail model, the standard tool for assessing a woman’s future risk
for breast cancer (Gail et al., 1989), high mammographic density or
Wolfe parenchymal pattern [based on patterns of ducts, nodularity and
densities seen on mammography (Wolfe, 1976)]; moderate risk was par-
ticipants with a history of any type of cancer or with ﬁrst degree relatives
with breast cancer; low risk was all other participants (Vachon et al.,
2007). Where more than one method was used to asses breast density,
as in the study by Atkinson (Atkinson et al., 2004; Kataoka et al., 2008),
data for the main analysis were used from the semi-automated assess-
ment, rather than the entirely visual or entirely automated assessments,
as semi-automated assessment appeared to be most commonly used
through the studies, although the visual and fully automated data were
also used in subgroup analyses. Data for the main analysis were taken
from the latest follow-up in each trial on the basis that any effect of isoﬂa-
vones are likely to be cumulative and so any differences are more likely to
be observed after a longer duration. Where studies did not provide data
on the change in breast density from baseline to study end, but only data
on mean breast density at study end, the end data were used within the
meta-analysis (as is considered appropriate in the Higgins and Green,
2008a), to make best use of the available data. Authors were contacted
for further data or clariﬁcation where questions arose.
Validity assessment of included studies was based on allocation conceal-
ment, masking of participants, masking of outcome assessors, industry
funding or involvement, whether compliance with the intervention was
measured and reported, whether isoﬂavone doses in intervention and
control arms were reported, and whether dropouts were clearly reported.
These characteristics [based on the method used by the Higgins and
Green (2008a)] were:
(i) Allocation concealment (concealment of the ability of those recruiting
participants to assess which arm participants will be randomized into
before recruitment is complete, coded as adequate, unclear or
inadequate);
(ii) participant blinding (concealment of the participants to whether they
are part of the intervention or control condition, coded as yes,
unclear or no);
(iii) outcome assessor blinding (concealment of the outcome assessor,
here the reader of the mammogram, to whether participants are
part of the intervention or control condition, coded as yes, unclear
or no);
(iv) industry funding or involvement [level of ﬁnancial involvement of
industries that may have a ﬁnancial interest in the study results,
coded as yes (study mainly funded by industry, or at least one
author is employed by industry), partly (other impartial funding, but
includes some industry funding that may include free provision of sup-
plements) or no];
(v) compliance assessed and reported [measurement of the degree to
which participants complied with taking the intervention and
control foods or supplements, and reporting of these data, coded
as yes (both reported), partly (one or the other) or no]; and
(vi) reporting of withdrawals (numbers of withdrawals in each group clear
and reasons reported coded as done, partial and not done).
Statistical analysis
Characteristics of included studies and study validity were tabulated
(Tables I and II). Differences in percentage mammographic density
between the isoﬂavone-rich intervention and control periods were com-
bined across studies using mean differences (MD) using a random
effects model in Review Manager 5.0 software (2008).
Where a study provided data in several different ways the data were
dealt with as follows for the main analysis: the data used were from all avail-
able participants (so that if there were two intervention groups and one
control group the data from the two intervention groups were combined
using the methods recommended in the Cochrane Handbook); from the
longest duration available; and using the semi-automated system of assess-
ment of breast density. In subgroup analyses, we used all available data; the
Powles study (Powles et al., 2008) which provided data at 1, 2 and 3 years
provided data into each of the three subgroups; the Atkinson study
(Atkinson et al., 2004; Kataoka et al., 2008) which used three methods
of assessment of breast density provided data into all three assessment
type subgroups; and the OPUS study (Maskarinec et al., 2009) which pro-
vided two doses of isoﬂavones provided data to two dose subgroups, with
the full control group used twice, so subgroups were not pooled.
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Table I Characteristics of included studies.
Study Participants Interventions Outcomes
Atkinson 2004, UK (Atkinson
et al., 2004; Kataoka et al.,
2008)
Participants: pre-, post- and peri- menopausal women
without breast cancer but with Wolfe P2 or DY
mammographic patterns
Form: tablet Duration: 52 weeks
Randomized: int 102, cont 103 Intervention: 1 tablet/day, Promensil (isolated
isoﬂavones from red clover) versus 1 tablet/day
placebo
Method of assessment: three methods used: visual
assessment by two independent radiologists,
computer-assisted using Cumulus and fully automated
using SMF—data on Cumulus used in our analysis
(% density)
Analysed: int 76, cont 84 Total isoﬂavone dose: int  44 mg/day, including
26 mg/day biochanin A, 16 mg/day formonetin,
1 mg/day genistein, 0.5 mg/day daidzein, cont
unclear (nil?)
Mean age (sd): int 55.1 (4.7), cont 55.2 (4.9)
Baseline risk: high
Marini 2008, Italy (Marini
et al., 2007, 2008; D’Anna
et al., 2009; Atteritano et al.,
2009)
Participants: post-menopausal osteopenic women
aged 49–67
Form: tablets Duration: 156 weeks
Randomized: int 198, cont 191 Intervention: 2 tablets/day puriﬁed genistein
(isolated aglycone genistein) versus 2 tablets/day
placebo
Method of assessment: computer-assisted
assessment (IMI)
Analyzed: at 2 years int 150, cont 154; At 3 years int
71, cont 67
Total isoﬂavone dose: int 54 mg/day genistein
(aglycone units), cont nil
Mean age (sd): int 53.8 (2.9), cont 53.5 (2.0)
Baseline risk: low
Maskarinec 2002, USA
(Maskarinec et al., 2002,
2003)
Participants: premenopausal women aged 35–46
with recent normal mammogram
Form: tablet Duration: 52 weeks
Randomized: int 17, cont 17 Intervention: 2 × 50 mg tablets/day soy extract
(isolated isoﬂavones) versus placebo (maltodextrin)
Method of assessment: computer-assisted
assessment (% density)
Analyzed: unclear, int 15, cont 15?? Total isoﬂavone dose: int 76 mg/day (aglycone
equivalents, 100 mg isoﬂavones) of total isoﬂavones,
including 38.8 mg/day daidzein, 33.4 mg/day
genistein, 3.8 mg/day glyceitin, cont unclear (nil?)
Mean age: int 41.1 (3.1), cont 43.3 (1.7)
Baseline risk: low
Maskarinec 2004a,b, USA
(Maskarinec et al., 2004a, b)
Participants: premenopausal women with clear
mammograms
Form: soy foods Duration: 104 weeks
Randomized: int 109, cont 111 Intervention: 2 servings/day soy foods versus usual
diet
Method of assessment: computer-assisted
assessment (% density)
Analyzed: int 98, cont 103 Total isoﬂavone dose: int  50 mg/day soy
isoﬂavones (aglycone equivalents), cont unclear
(usual diet)
Mean age (sd): int 43.2 (3.1), cont 42.8 (2.9)
Baseline risk: low
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.Maskarinec 2009 (OPUS),
USA (Maskarinec et al.,
2009)
Participants: early post-menopausal women aged 40–
60
Form: tablets Duration: 104 weeks
Randomized: int A 136, int B 135, cont 135 Intervention: 80 or 120 mg/day isoﬂavones from soy
germ (isolated isoﬂavones) versus placebo tablets
Method of assessment: computer-assisted
assessment by one assessor (% density)
Analyzed (2 yrs): int A 109, int B 100, cont 116 Total isoﬂavone dose: int A 120 mg/day isoﬂavones
(aglycone equivalents), including 1.2 mg/day
genistein, 15.6 mg/day genistin, 2.4 mg/day daidzein,
50.4 mg/day daidzein, 46.8 mg/day glyceitin, 3.6 mg/
day glyceitein, int B 80 mg/day isoﬂavones, 2/3
content int A for subfractions, cont unclear
Mean age (sd): int A 54.7 (3.8), int B 55.2 (4.0), cont
54.8 (3.6)
Baseline risk: low
Powles 2008, UK (Powles
et al., 2008)
Participants: pre-, post-, and peri-menopausal women
aged 35–69 with a ﬁrst degree relative with breast
cancer
Form: tablet Duration: 156 weeks
Randomized: int 199, cont 202 Intervention: 1/day red clover isolate tablet,
Promensil (isolated isoﬂavones) versus placebo tablet
Method of assessment: visual assessment (% density)
Analyzed: int 119 (111 pre-, 8 post-menopausal),
cont 112 (111 pre- and 11 post-menopausal)
Total isoﬂavone dose: 40 mg/day total isoﬂavones
Mean age: mean unclear, medians: int 45, cont 45
Baseline risk: moderate
Tice 2009 (PREVENT), USA
(Tice et al., 2005; Tice, 2006)
Participants: otherwise healthy premenopausal
women with breast density ≥50%
Form: protein powder (taken in smoothies or added
to other foods and drinks)
Duration: 26 weeks
Randomized: int 24, cont 23 Intervention: 25 g/day soy protein (ISP) versus 25 g/
day milk protein
Method of assessment: computer-assisted threshold
method, using craniocaudal view (% density)
Analyzed: int 20, cont 20 Total isoﬂavone dose: int 50 mg/day isoﬂavones
(aglycone equivalents), cont 0 mg/day isoﬂavones
Mean age (sd): int 44.8 (sd unclear), cont 44.6 (sd
unclear)
Baseline risk: moderate
Verheus 2008 (Finesse)
Netherlands (Kok et al.,
2004, 2005a, b;
Kreijkamp-Kaspers et al.,
2005, 2009; Verheus et al.,
2009)
Participants: healthy post-menopausal women aged
60–75 with a recent normal mammogram
Form: powder to be mixed with food or drink Duration: 52 weeks
Randomized: int 100, cont 102 Intervention: 25.6 g/day Solae soy protein (ISP)
versus 25.6 g/day milk protein
Method of assessment: computer-assisted
assessment (% density)
Analyzed: int 70, cont 56 Total isoﬂavone dose: int 99 mg/day isoﬂavones
(aglycone units), including 52 mg/day genistein,
41 mg/day daidzein, 6 mg/day glyceitin, cont nil
Mean age (sd): int 66.3 (4.3), cont 65.3 (4.0)
Baseline risk: low
ISP, isolated soy protein; Cont, control group; Int, intervention group; Isoﬂav, isoﬂavone/s; FP, food provided; DO, dropouts; sd, standard deviation; ISP, isolated soy protein; % density, percent density; SMF, Standard Mammogram Form, which is
a fully automated volumetric computer method.
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Table II Validity of included studies.*
Study Allocation
concealment
Masking of
participants
Masking of
outcome
assessors
Industry funding or
involvement
Compliance assessed
and reported
Reporting of
withdrawals
Atkinson 2004 Yes Yes Yes Partly (some funding from
non-industry sources, some from
Novogen Ltd)
Done, urinary isoﬂavones Partial
Marini 2008 Unclear Yes Yes Partly (some funding from
non-industry sources, some from
Primus Pharmaceuticals, two authors
work for Primus Pharmaceuticals)
Done, serum genistein Done
Maskarinec 2002 Unclear Yes Yes Yes, funding from Pharmavite
Corporation
Done, urinary isoﬂavones and tablet
count
Done
Maskarinec 2004 Unclear No Yes Partly (funding from non-industry
source, food donations from Aloha
Tofu, Dr Soy, Solae Company)
Done, urinary isoﬂavones, intake logs,
24 h recalls
Partial
Maskarinec 2009
OPUS
Unclear Yes Yes Unclear (funded by NIH but unclear if
study paid for the tablets or not)
Partly done, blood isoﬂavones and pill
counts, results not reported
Done
Powles 2008 Unclear Yes Unclear Partly (funding from non-industry
source, supplement supplied by
Novogen Ltd)
Not done Partial
Tice 2009
(PREVENT)
Yes Yes Yes None (US Army) Done, packet count at 6 mo. Done
Verheus 2008
(Finesse)
Yes Yes Yes Partly (some funding from
non-industry sources, some from
DuPont Protein Technologies)
Done, serum genistein, counts of
powder bags, diary
Done
*Trial quality characteristics assessed included: (i) allocation concealment (concealment of the ability of those recruiting participants to assess which arm participants will be randomized into before recruitment is complete, coded as adequate,
unclear or inadequate); (ii) participant masking (concealment of the participants to whether they are part of the intervention or control condition, coded as ‘yes’ where there was a clear and realistic attempt to mask, ‘no’ where not, or ‘unclear’);
(iii) outcome assessor blinding (concealment of the outcome assessor, here the reader of the mammogram, to whether participants are part of the intervention or control condition, coded as ‘yes’ where there was a clear and realistic attempt to
mask, ‘no’ where not, or ‘unclear’); (iv) industry funding or involvement [level of ﬁnancial involvement of industries that may have a ﬁnancial interest in the study results, coded as yes (study mainly funded by industry, or at least one author is
employed by industry), partly (other impartial funding, but includes some industry funding that may include free provision of supplements) or no]; (iv) compliance assessed and reported (measurement of the degree to which participants complied
with taking the intervention and control foods or supplements, and reporting of these data, coded as ‘done’ when compliance was both assessed and reported, ‘partly done’ when it was assessed but not reported or reported without any
indication of the method used, and ‘not done’ when neither was addressed adequately); and (v) reporting of withdrawals [numbers of withdrawals in each group clear and reasons reported coded as done, reported as ‘done’ when numbers
randomized, completed and analysed all clear, plus reasons for dropouts given (by intervention arm), ‘partially done’ when some of the above, ‘not done’ when not].
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data, but data on no participants were included twice. Subgrouping was
used to explore the effects of the following factors on breast density:
(i) source of isoﬂavones (soy-based foods, soy protein, soy germ, isoﬂa-
vones isolated from soy, isoﬂavones isolated from red clover, pure
genistein, pure daidzein);
(ii) participants baseline risk of breast cancer (high, moderate or low);
(iii) isoﬂavone dose (in aglycone equivalents, ,50, 50 to ,100,
100+ mg/day)
(iv) duration of intervention (6 to ,18, 18 to ,30 and 30+ months);
and
(v) method of assessment of breast density (visual assessment, semi-
automated and fully automated assessment).
It was intended that we would also subgroup by participants who were
equol producers compared with those who were non-equol producers,
however, there were insufﬁcient data on breast density by equol producer
status for this to be feasible. The equol producer phenotype is thought to
be important as levels of this gut metabolite of the soy isoﬂavone daidzein
have been inversely associated with breast cancer risk. In humans only
30–50% of the population harbour the bacteria capable of converting
daidzein to equol, and this metabolite has biological activities that differ
from its parent compound, e.g. relative binding afﬁnity to estrogen recep-
tors (Cassidy et al., 1994; Duncan et al., 1999; Lampe, 2009).
Sensitivity analysis was used to assess robustness of results. Sensitivity
analyses were carried out to:
(i) include all breast density measures using standardized mean differ-
ence analysis [which allowed the Marini data (Marini et al., 2008),
not measured using percentage breast density but using image
mean index (IMI) which cannot be translated into percent breast
density, to be included],
(ii) exclude studies wholly funded by industry (Lexchin et al., 2003), and
(iii) use the P-values provided for the Powles study ((Powles et al., 2008),
as the 95% CIs did not appear to correlate with the P-values provided
in the same table. As we were not able to initiate discussion with the
authors, both the CIs and the P-values were used to compute stan-
dard deviations used in the analyses (2008a), the P-value data were
used as a sensitivity analysis).
Type and frequency of side effects, diagnosis of breast cancer, deaths and
study withdrawals were tabulated and compared between different
studies. Heterogeneity was assessed using Cochran’s test and the I
2 test
(and assumed to be present when I
2 . 50%; Higgins et al., 2003).
Funnel plots were used to assess for evidence of publication bias (Egger
et al., 1997). This manuscript follows the criteria suggested for systematic
reviews in the PRISMA guidelines (Moher et al., 2009).
Results
Description of included studies
A total of 678 titles and abstracts were screened following the elec-
tronic and bibliographic searches. Of these 74 appeared potentially
relevant and were ordered as full text papers to be assessed for
inclusion independently in duplicate. Eight of these RCTs (published
in 18 full text papers, one unpublished manuscript and an abstract)
were included in the review (Fig. 1).
The eight included studies randomized 1904 women between
them, and analysed data on 1287 after study durations of between
6 months and 3 years (Table I). Five of the studies included post-
menopausal women, and ﬁve included premenopausal women (two
studies included both groups). The baseline risk of breast cancer
was low in most studies, moderate in one (including pre-, post- and
peri-menopausal women with a ﬁrst degree relative with breast
cancer (Powles et al., 2008), and high in two studies (including preme-
nopausal women with a Gail risk of at least 1.67 and .50% breast
density at initial mammogram (Tice, 2006), and pre-, post- and peri-
menopausal women with Wolfe P2 or DY mammographic patterns
but without breast cancer (Atkinson et al., 2004). Four studies were
conducted in Europe, four in the USA.
Two studies provided red clover-based isoﬂavone supplements,
three soy-based isoﬂavone supplements (one pure genistein, one
soy germ based isoﬂavones and one mixed soy isoﬂavones), one pro-
vided additional soy foods and two provided soy protein powder com-
pared with milk protein powder. Isoﬂavone doses ranged from 40 to
120 mg/d. Control groups received other ‘inert’ or ill-deﬁned sub-
stances low in isoﬂavones, advice to eat their usual diet or milk
protein in place of soy protein.
All studies calculated mammographic percentage density except
one (Marini et al., 2008) which calculated IMI, in arbitrary units. This
outcome was assessed visually in one study, using a computer-assisted
method in six and assessed using three methods (a visual method, a
computer-assisted method and a fully computerized method) in one
study.
All included studies were fully published in at least one journal
article, except for the study by Tice which was informally published
(Tice et al., 2005; Tice, 2006). The unpublished study by Tice was a
double blinded, randomized trial of 6 months of daily soy protein con-
taining 50 mg of isoﬂavones with a primary outcome of change in per-
centage mammographic breast density timed to the menopause cycle.
For this trial data on the study were extracted from the study protocol
and ﬁnal report to the funders (Tice, 2006). As with other included
studies the author was asked for further information.
Risk of bias
Allocation concealment was unclear in all studies except those by
Atkinson, Verheus and Tice (Atkinson et al., 2004; Tice, 2006;
Verheus et al., 2009), where it was clearly concealed. Attempts
were made to mask participants in all studies except one (Maskarinec
et al., 2004a, b), which was a food-based intervention. Masking of
outcome assessors was attempted in all of the studies, except that
by Powles et al. (2008) where masking of outcome assessors was
unclear. Most studies were funded jointly by industry and non-industry
sources, except for one of the Maskarinec trials (Maskarinec et al.,
2003) which was funded solely by industry, the Tice study (Tice,
2006) which was exclusively funded by non-industry sources and
OPUS (Maskarinec et al., 2009) which was unclear (though appeared
to be mainly funded by non-industry sources). Most studies assessed
compliance with the intervention and placebo, and reported results
of this assessment, except that OPUS (Maskarinec et al., 2009)
reported the method of assessment but not any results, and the
Powles study (Powles et al., 2008) did not report either a method-
ology for assessing compliance or any results. Reporting of withdra-
wals was done for ﬁve studies and partially done for three
(Atkinson et al., 2004; Maskarinec et al., 2004a, b; Powles et al., 2008).
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There was no evidence of an overall effect of isoﬂavones on percen-
tage breast density from seven studies including 1149 participants
for at least 6 months each (mean difference 0.69%, 95% CI 20.78
to 2.17) and no evidence of heterogeneity [Fig. 2; this analysis
excluded the eighth study, that did not use percentage breast
density as a measure (Marini et al., 2008)]. Sensitivity analyses includ-
ing the Marini study [the study assessing breast density using a different
measure (Marini et al., 2008)], or excluding studies wholly funded by
industry, or using Powles P-value data [(Powles et al., 2008) rather
than the CIs presented] similarly did not suggest any overall effect
(Table III).
Analysis subgrouping by menopausal status resulted in an analysis
that included slightly fewer women than were included in the overall
analysis as some women from the Atkinson study had not been
clearly allocated to a particular menopausal status. In premenopausal
women isoﬂavone intake resulted in a modest increase in mammo-
graphic percent density compared with controls (mean difference
1.83%, 95% CI 0.25–3.40, n ¼ 519, 5 trials) with no evidence of het-
erogeneity (P ¼ 0.85, I
2 ¼ 0%; Fig. 3). In contrast, in post-menopausal
women, isoﬂavone intervention had no effect on breast density (mean
difference 21.10%, 95% CI 23.22 to 1.03, n ¼ 592, 4 trials) and
there was no evidence of heterogeneity (P ¼ 0.23, I
2 ¼ 30%). There
was no signiﬁcant effect in the few peri-menopausal women (mean
difference 20.37%, 95% CI 26.12 to 5.38, n ¼ 16, 1 trial).
Sensitivity analyses, using the P-value data from the Powles study
(Powles et al., 2008), rather than the CI data (as these did not corre-
spond, see the statistical analysis section of the Methodology above),
resulted in marginal loss of statistical signiﬁcance in this subgroup (P ¼
0.05). Including, or not, the Marini study data [(Marini et al., 2008), not
expressed as breast density] did not alter these ﬁndings (the effects in
premenopausal women were still statistically signiﬁcant, see Table III).
Removal of studies with some industry funding would remove almost
all studies, but removal of the one study which was solely industry
funded (Maskarinec et al., 2002) did not result in loss of the statistically
signiﬁcant effect of isoﬂavones on breast density in premenopausal
women.
Subgrouping by duration suggested that there may possibly be an
increase in breast density compared with controls in the long-term
trials (3 years) although the signiﬁcance was only marginal (mean
difference 3.22%, 95% CI 20.18 to 6.63, P ¼ 0.06, 2 trials including
241 participants, with no evidence of heterogeneity; Fig. 4).
From the available evidence, there was little suggestion of differen-
tial effects of isoﬂavone source, isoﬂavone dose, baseline risk of breast
cancer or type of assessment technique for breast density (Table III).
The funnel plot was ineffective in assessing whether there was a risk of
publication bias as most studies were of a similar size, and so the plot
is difﬁcult to interpret (Fig. 5).
Effect of isoﬂavones on breast cancer,
dropouts and adverse events
As anticipated there were too few cases of breast cancer or deaths
reported to draw conclusions on the effects of isoﬂavones on these
outcomes (Table IV).
Gastrointestinal complaints were commonly reported side effects,
and meta-analysis of studies reporting dropouts due to gastrointestinal
problems did not suggest a statistically signiﬁcant difference between
intervention and control arms (RR 1.49, 95% CI 0.69–3.24, 4
studies, 870 participants). However, there was strong heterogeneity
between studies (P 0.07, I
2 63%), which will have been accommodated
Figure 1 Flowchart illustrating movement of papers from search to inclusion.
752 Hooper et al.through use of random effects meta-analysis. Individually, one study
suggested signiﬁcantly greater numbers of dropouts due to gastroin-
testinal problems in the intervention group (Marini et al., 2008),
although the others suggested no signiﬁcant differences (Maskarinec
et al., 2004a, b; Powles et al., 2008; Verheus et al., 2009).
Other side effects were reported by Powles et al. (2008) (they
noted breast abnormalities, weight gain, skin problems and lethargy,
of which only weight gain appeared to be different between interven-
tion and control arms—those on the intervention were less likely to
report weight gain than those in the control group). Weight gain
caused one participant to drop out of the control group of the Tice
study (Tice, 2006), but did not affect other participants.
There was no signiﬁcant difference in dropouts due to any cause
between intervention and control arms (RR 1.14, 95% CI 0.96–
1.35, 7 studies, 1870 participants, no signiﬁcant heterogeneity).
Discussion
We included eight RCTs of isoﬂavones versus placebo or control diet
with a duration of at least 6 months that assessed effects on breast
density in women. These analyses included 1287 participants included
in dietary intervention trials for between 6 months and 3 years.
Although the available studies individually suggest that there is no
effect overall on breast density following dietary isoﬂavone interven-
tion, data from this meta-analysis provide evidence of a modest
increase in breast density in premenopausal women taking isoﬂavones
compared with control, and the effect may be greater in longer
studies. These effects were small (a 1.83% increase in breast density
compared with controls for premenopausal women) and although
the clinical relevance of this potential relationship merits further inves-
tigation there are no immediate implications for practice.
In contrast, no signiﬁcant effect was observed in post-menopausal
women and to date only one trial has conducted analysis on a small
number of peri-menopausal women (Atkinson et al., 2004; Kataoka
et al., 2008). There were insufﬁcient data to directly assess effects
of isoﬂavones on breast cancer or mortality.
The doses of isoﬂavone fed in the trials ranged from 40 to 120 mg/
day (aglycone equivalents). However, across this wide range in intake,
there was little suggestion of differential effects by dose. The source of
isoﬂavone did not signiﬁcantly alter the observed effect.
The method used to assess breast density varied across the trials
and this may affect the relative readings of breast densities in different
groups. Kataoka assessed breast density using three separate tech-
niques and found that the methods were not equivalent, conﬁrming
previous studies (Kataoka et al., 2008; Yaffe, 2008). We used the
semi-automated assessment data from Atkinson and Kataoka within
the main analyses (as this was the most common type of assessment
across the different studies—this was chosen by a researcher blinded
to the outcome measures), however, these suggest a larger effect of
isoﬂavones on breast density than either of the other methods. Devel-
opment of more robust methodology would be helpful in allowing
assessment of effects in future studies (Yaffe, 2008).
Other dietary components and hormonal factors have previously
been shown to modify breast density (Boyd et al., 1997, 2001;
Greendale et al., 2003) and our previous systematic review of isoﬂa-
vone and hormonal status suggested modest effects of isoﬂavones on
gonadotrophins and estradiol in women (Hooper et al., 2009).
However, to our knowledge this is the ﬁrst systematic review of
Figure 2 Main analysis, subgrouping by baseline risk of breast cancer, using only percentage breast density data (mean difference analysis).
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graphic density.
In epidemiological settings, studies in high soy-consuming
Asian populations suggest a reduction in breast cancer risk with
increased habitual intake of soy; risk was lowest in those consuming
≥20 mg/day although the data were largely based on case–control
studies and an inverse association was observed in both pre- and post-
menopausal women (Wu et al., 2008). Recent data from Chinese
breast cancer patients, where the range in soy intake is large
enough to provide heterogeneity in isoﬂavone intake, showed that
soy food consumption was signiﬁcantly associated with decreased
risk of death and recurrence and a linear dose–response effect
was observed up to an isoﬂavone intake of 40 mg/day (Shu et al.,
2009). However, these protective effects stem from consumption of
traditional soy food and there is currently no epidemiological evidence
for beneﬁcial effects of dietary supplements derived from soy or red
clover, such as were tested in many of our included studies.
The beneﬁcial effects seen in observational studies may relate to life-
time or early life exposure to soy isoﬂavones, and the strongest and
most consistent effect is related to childhood soy intake (Wu et al.,
2002; Korde et al., 2009). Isoﬂavones may exert their potential protec-
tive effects early in life by stimulating breast cell differentiation (Lamarti-
niere,2000;Lamartiniereetal.,2002)butthesepositiveepidemiological
data are in contrast to the conﬂicting experimental data from in vitro
models and studies in animal models including the ovarectomized
athymic nude mouse model implanted with MCF-7 cells (an estrogen-
sensitive breast cancer cell line; Wang et al., 1996; Hsieh et al., 1998;
Allred et al., 2001, 2004a, b; Ju et al., 2001; Kanno et al., 2003; Power
.............................................................................................................................................................................................
Table III Subgrouping and sensitivity analyses.
Factor Subgroup Number
of studies
Number of
participants
Mean difference (95%
CI)
P-value for
heterogeneity, I
2
Main analysis Overall analysis (no subgroups) 7 1149 0.69 (20.78 to 2.17) 0.14, 36%
Menopausal status* Premenopausal 5 519 1.83 (0.25 to 3.40) 0.85, 0%
Post-menopausal 4 592 21.10 (23.22 to 1.03) 0.23, 30%
Peri-menopausal 1 16 20.37 (26.12 to 5.38) NR
Baseline risk of breast cancer Low risk 4 715 0.97 (20.77 to 2.71) 0.72, 0%
Moderate risk 2 241 3.22 (20.18 to 6.63) 0.62, 0%
High risk 2 194 20.24 (23.47 to 2.99) 0.07, 69%
Isoﬂavone source Isolated red clover isoﬂavones 3 394 0.70 (23.37 to 4.76) 0.04, 69%
Isolated soy isoﬂavones 1 30 2.12 (22.42 to 6.66) NR
Soy foods 2 559 0.54 (21.71 to 2.79) 0.34, 0%
Soy protein 2 166 1.54 (20.83 to 3.92) 0.85, 0%
Any soy intervention 5 755 1.14 (20.40 to 2.68) 0.82, 0%
Dose, mg/day total
isoﬂavones**
,50 3 394 0.70 (23.37 to 4.76) 0.04, 69%
50 to ,100 5 635 0.90 (20.74 to 2.54) 0.36, 8%
100+ 1 243 1.30 (23.38 to 5.98) NR
Duration** 6 to ,18 months 7 1014 20.20 (21.29 to 0.88) 0.33, 13%
18 to ,30 months 4 846 0.08 (21.34 to 1.51) 0.65, 0%
30+ months 2 241 3.22 (20.18 to 6.63) 0.62, 0%
Type of density assessment** Visual assessment 1 160 0.70 (22.95 to 4.35) NR
Semi-automated 7 1023 0.67 (21.01 to 2.36) 0.11, 43%
Fully automated 2 277 20.22 (21.57 to 1.13) 0.34, 0%
Sensitivity analyses
SMD analysis including all
breast density measures
Overall analysis 8 1287 0.06 (20.09 to 0.21) 0.09, 39%
Premenopausal 4 479 0.21 (0.04 to 0.38) 0.95, 0%
Post-menopausal 5 730 20.07 (20.33 to 0.18) 0.05, 57%
Peri-menopausal 1 16 20.07 (21.05 to 0.92) NR
Excluding studies fully funded
by industry
Overall analysis 7 1119 0.60 (21.00 to 2.19) 0.12, 41%
Premenopausal 4 489 1.79 (0.11 to 3.47) 0.72, 0%
Post-menopausal 5 730 20.07 (20.33 to 0.18) 0.05, 57%
Peri-menopausal 1 16 20.07 (21.05 to 0.92) NR
Using Powles P-value data Overall analysis (no subgroups) 7 1149 0.43 (20.91 to 1.77) 0.24, 23%
Premenopausal 5 519 1.63 (20.03 to 3.30) 0.94, 0%
Post-menopausal 4 592 20.89 (23.04 to 1.26) 0.18, 38%
Peri-menopausal 1 16 20.37 (26.12 to 5.38) NR
CI, conﬁdence intervals; NR, Not relevant (assessment of heterogeneity is not relevant when only one study is included).
*As the menopausal status of some of the Atkinson study participants was not known the total numbers of participants are smaller when subgrouped by menopausal status than in the
overall analysis.
**In some studies data were measured at more than one time point or using more than one technique, so numbers do not add up to total numbers of study participants. One study used
two different dose levels and as these arms fell in separate dose subgroupings the full control group was used once in each subgroup, increasing the apparent number of participants.
754 Hooper et al.Figure 3 Subgrouping by menopausal status, using only percentage breast density data (mean difference analysis).
Figure 4 Subgrouping by study duration, only percentage breast density data (mean difference analysis).
Isoﬂavones and breast density systematic review 755et al., 2006a, b, 2007; Seo et al., 2006; Cline and Wood, 2009; Messina
et al., 2009; Messina and Wu, 2009; Saarinen et al., 2009). Our ﬁndings
from the available RCTs support the epidemiological data observed for
post-menopausal women but not for premenopausal women as we
observed a small increase in breast density following isoﬂavone con-
sumption in the younger women.
Figure 5 Funnel plot assessing risk of publication bias (plotting mean difference in breast density vs. the standard error of the mean difference).
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.............................................................................................................................................................................................
Table IV Breast cancer diagnoses, mortality and side effects in included studies.
Study Diagnoses of breast
cancer during study
Deaths from any cause
during the study
Reported side effects
Isoﬂavone
arm(s)
Placebo
arm
Isoﬂavone
arm(s)
Placebo
arm
Isoﬂavone arm(s) Placebo arm
Atkinson
2004
1/102 0/103 NR NR NR NR
Marini 2008 0 0 0 0 37/150 GI complaint 15/154 GI complaint
Maskarinec
2002
NR NR NR NR NR NR
Maskarinec
2004
NR NR NR NR 0/108 adverse effects 0/110 adverse effects
Maskarinec
2009 OPUS
NR NR NR NR Several droppedoutdue toGIcomplaintsinbotharms,butnumbersunclear
Powles 2008 3/199 5/202 NR NR 9/111 GI complaint, 7/111
weight gain
6/111 GI complaint, 13/111 weight gain
Tice 2009
PREVENT
0/24 0/23 0/24 0/23 3/20 upset stomach, 3/20
constipation, 2/20 heartburn,
0/20 hot ﬂashes, 1/20
diarrhoea
4/20 upset stomach,
3/20 constipation,
1/20 heartburn, 2/20 hot ﬂashes,
1/20 diarrhoea,
Verheus 2008
(Finesse)
0 0 0 0 7/70 GI complaint 8/56 GI complaint
GI, gastrointestinal; NR, not reported.
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and breast density (Masala et al., 2009; Reeves et al., 2009) which
might confound the relationship between isoﬂavones and breast
density in epidemiological studies. However, there was no evidence
of weight or BMI being consistently different in intervention and
control groups in a way that could confound the relationship
between isoﬂavone supplementation and breast density in our ana-
lyses of these dietary intervention trials. There was little information
provided on physical activity, and although it is possible that individual
relatively small studies may have been unbalanced with regards to
physical activity, this is unlikely across the whole set of studies
unless there was a speciﬁc bias in place. Despite the limitations of
the included studies, their randomized controlled design will have con-
trolled for any confounding by socioeconomic status, BMI, differential
weight change, other health behaviours such as physical activity or
interest in healthy eating for example, that may be manifest in epide-
miological studies.
A further factor that may affect breast density readings is the timing
of a mammogram within the menstrual cycle in premenopausal
women. A review (Martin and Boyd, 2008) found little evidence of
effects of steroid sex hormones on premenopausal mammographic
density, whereas two more recent studies have found relationships
between levels of endogenous hormones and breast density in preme-
nopausal women (Walker et al., 2009; Yong et al., 2009). The effect of
the menstrual cycle on breast density has also been studied directly.
Several studies showed that variations in density during the cycle are
small and not clinically important (Buist et al., 2006; Hovhannisyan
et al., 2009), whereas Ursin et al.( 2001) found that while changes
were generally small, in some women they were more signiﬁcant,
suggesting that mammograms should be collected in the follicular
phase of the cycle. This study echoed the ﬁndings of an earlier
study (White et al., 1998) which was speciﬁc to women in their
40s. In our systematic review, of the six studies in premenopausal
women menstrual cycle phase was mentioned only in one (Tice,
2006), in which the ﬁnal report stated that mammograms were col-
lected during Days 7–13 of the cycle. In three studies it was unlikely
that phase had been taken into account as mammograms were taken
as part of normal screening activities (Atkinson et al., 2004; Maskari-
nec et al., 2002, 2004a, b), and no details of timing were provided
in the others. If phase of the menstrual cycle is important in breast
density then lack of timing of mammograms is likely to make it
more difﬁcult to see any changes in breast density that may occur dif-
ferentially over time.
Overall, the studies included were of moderate risk of bias.
Whereas masking, assessment of compliance and reporting of with-
drawals were generally carried out appropriately and well reported,
allocation concealment was unclear in all but two trials, and industry
at least partly funded almost all of the studies. Allocation concealment
has been associated with bias in a pooled analysis of methodological
studies, suggesting that inadequate or unclear reporting of allocation
concealment treatments were 18% more beneﬁcial than in studies
with adequate allocation concealment (Pildal et al., 2007). However,
this bias appears to be manifest in studies with subjective outcomes,
and not objective ones, suggesting that the masking of outcome asses-
sors to allocation, and method of assessment of breast density may be
important in study outcomes (Wood et al., 2008). The predominance
of industry funding for the studies may be expected to potentially lead
to exaggerated suggestions of effectiveness, minimized suggestions of
risk or publication bias (Lesser et al., 2007). Data from the Powles
study were difﬁcult to interpret as the 95% CIs presented did not cor-
respond with the P-values presented for the same effect, and we were
unable to elicit any discussion on this with the authors (Powles et al.,
2008). As a result we ran the analysis ﬁrst using the 95% CIs (as these
were the most accessible), then ran a sensitivity analysis using the data
from the P-values. The observed effect in premenopausal women was
attenuated when the data from P-values, rather than 95% CIs, were
used in analysis, but the pooled effect was still apparent (Table III,
the effect in premenopausal women became a mean difference of
1.63% (95% CI 20.03 to 3.30, P ¼ 0.05)).
Conclusions
Implications for practice
Isoﬂavones from different sources had no effect on breast density in
post-menopausal women and a small effect in premenopausal
women. The average 5 year absolute risk for breast cancer for a
50-year-old woman in the USA is 1.3%. The relative risk of breast
cancer for a women with a breast density of 5–24% ( 15%), com-
pared with a woman with a breast density of ,5% ( 3%), is 1.79
(95% CI 1.48–2.16; McCormack and dos Santos Silva, 2006). As
there appears to be an approximately linear relationship between
RR and breast density moving from 3% density to 15% density is
associated with a RR of 1.79, and increasing breast density by 1.83%
would equate with a RR of 1.12. The 5 year risk for the average
woman would therefore move from 1.3 to 1.46%. This does not
seem to be of sufﬁcient magnitude to justify any recommendation
regarding isoﬂavone foods or supplements. Although the clinical rel-
evance of this potential relationship merits further investigation
there are no immediate implications for practice.
Implications for research
In the absence of sufﬁcient data on the effects of isoﬂavones on breast
cancer diagnoses it would be helpful to assess effects of isoﬂavones on
breast density in premenopausal women in a large and high quality
RCT of at least 4 years duration and which assesses breast density
at a consistent point in the menstrual cycle.
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